Can MRI reveal the hidden progression of muscular dystrophy?
NCT ID NCT01671865
First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time
Summary
This study is looking at how magnetic resonance imaging (MRI) and spectroscopy can be used to detect and track changes in the muscles of people with facioscapulohumeral muscular dystrophy (FSHD). The goal is to identify reliable biomarkers—measurable indicators of disease activity—that could help in future research and clinical trials. Participants will undergo MRI scans and physical assessments, including muscle strength and timed function tests, to see how imaging findings relate to real-world muscle function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Magnetic resonance imaging and spectroscopy (non-invasive imaging techniques)
- What this could lead to
- If successful, this could establish reliable biomarkers to monitor disease progression and evaluate potential treatments in future clinical trials for FSHD.
- What could go wrong
- This is an observational study, so it won't directly test a treatment. The findings may not translate into immediate clinical benefits, and imaging changes may not perfectly correlate with muscle function.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Doris Leung
Baltimore, Maryland, 21205, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Personalized exercise program aims to boost mobility in rare muscle diseases
- New tools aim to speed up FSHD drug trials
- New tool could better track facial muscle health in rare muscle disease
- New drug aims to build muscle in rare muscular dystrophy
- FSHD patients unite: new registry aims to accelerate research and care
- Sound waves could spot early signs of rare muscle disease